WallStreetZenWallStreetZen

NYSEMKT: CHRO
Chromocell Therapeutics Corp Stock

$1.50+0.13 (+9.49%)
Updated Jun 24, 2024
CHRO Price
$1.50
Fair Value Price
N/A
Market Cap
$8.65M
52 Week Low
$1.21
52 Week High
$6.00
P/E
-0.21x
P/B
7.65x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$8.98M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
2.57
Operating Cash Flow
-$3M
Beta
-0.05
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CHRO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CHRO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CHRO is poor value based on its book value relative to its share price (7.65x), compared to the US Biotechnology industry average (6.29x)
P/B vs Industry Valuation
CHRO is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CHRO due diligence checks available for Premium users.

Be the first to know about important CHRO news, forecast changes, insider trades & much more!

Valuation

CHRO price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.21x
Industry
-6.96x
Market
30.03x

CHRO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
7.65x
Industry
6.29x
CHRO is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CHRO's financial health

Profit margin

Revenue
$0.0
Net Income
-$2.6M
Profit Margin
0%
CHRO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$4.0M
Liabilities
$2.9M
Debt to equity
2.57
CHRO's short-term assets ($4.03M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CHRO's short-term assets ($4.03M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CHRO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.0M
Investing
$0.0
Financing
$5.7M
CHRO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CHRO vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CHRO$8.65M+9.49%-0.21x7.65x
IKT$8.61M-5.00%-0.40x1.27x
KA$8.95M+13.18%-0.49x-1.40x
MBRX$8.34M-3.48%-0.28x0.39x
BNOX$8.99M+0.91%0.02x0.47x

Chromocell Therapeutics Stock FAQ

What is Chromocell Therapeutics's quote symbol?

(NYSEMKT: CHRO) Chromocell Therapeutics trades on the NYSEMKT under the ticker symbol CHRO. Chromocell Therapeutics stock quotes can also be displayed as NYSEMKT: CHRO.

If you're new to stock investing, here's how to buy Chromocell Therapeutics stock.

What is the 52 week high and low for Chromocell Therapeutics (NYSEMKT: CHRO)?

(NYSEMKT: CHRO) Chromocell Therapeutics's 52-week high was $6.00, and its 52-week low was $1.21. It is currently -75% from its 52-week high and 23.97% from its 52-week low.

How much is Chromocell Therapeutics's stock price per share?

(NYSEMKT: CHRO) Chromocell Therapeutics stock price per share is $1.50 today (as of Jun 24, 2024).

What is Chromocell Therapeutics's Market Cap?

(NYSEMKT: CHRO) Chromocell Therapeutics's market cap is $8.65M, as of Jun 25, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Chromocell Therapeutics's market cap is calculated by multiplying CHRO's current stock price of $1.50 by CHRO's total outstanding shares of 5,766,704.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.